Pawar et al Journal of Drug Delivery & Therapeutics. 2019; 9(4-A):260-268 ISSN: 2250-1177 [260] CODEN (USA): JDDTAO Available online on 30.08.2019 at http://jddtonline.info Journal of Drug Delivery and Therapeutics Open Access to Pharmaceutical and Medical Research © 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted non-commercial use, provided the original work is properly cited Open Access Research Article Formulation and Evaluation of Sustained Release Matrix Tablets of Captopril Pawar Simran S.*, Malpure Prashant S., Surana Santosh S., Bhadane Jayashri S. Department of Pharmaceutics, Loknete Dr. J.D. Pawar College of Pharmacy, Manur, Tal-Kalwan, Dist-Nashik (Maharashtra) 423501 ABSTRACT The objective of the present study was to study the effect of polymers on sustained release of Captopril from tablets. Compatibility was studied by Fourier transform infrared spectroscopy and DSC. The tablets were prepared by direct compression technique using Xanthan gum and Ethyl Cellulose. The prepared matrix tablets were evaluated for their physicochemical parameters such as weight variation, hardness, friability, content uniformity and in-vitro dissolution. Pre and post compression parameters were evaluated and all the parameters were found within the limit. The drug release data were subjected to different models in order to evaluate release kinetics and mechanism of drug release. Formulation F4 was selected as best formulation. The dissolution of formulation F4 can be Shows Non-fickian drug release mechanism. Keywords: Matrix tablets, Captopril, Xanthan gum, Ethyl cellulose. Article Info: Received 18 July 2019; Review Completed 23 Aug 2019; Accepted 27 Aug 2019; Available online 30 Aug 2019 Cite this article as: Pawar SS, Malpure P.S., Surana S.S., Bhadane J.S., Formulation and Evaluation of Sustained Release Matrix Tablets of Captopril, Journal of Drug Delivery and Therapeutics. 2019; 9(4-A):260-268 http://dx.doi.org/10.22270/jddt.v9i4- A.3406 *Address for Correspondence: Miss. Pawar Simran S., Department of Pharmaceutics, Loknete Dr. J.D. Pawar College of Pharmacy, Manur, Tal-Kalwan, Dist-Nashik (Maharashtra) 423501 INTRODUCTION Sustained release technology is relatively new field and as a consequence, research in the field has been extremely fertile and has produced many discoveries. With many drugs, the basic goal is to achieve a steady state blood level that is therapeutically effective and non-toxic for an extended period of time. The design of proper dosage form is an important element to accomplish this goal. Sustained release, sustained action, prolonged action, controlled release, extended action, timed release and depot dosage form are term used to identify drug delivery system that are designed to achieve prolonged therapeutic effect by continuously releasing medication over an extended period of time after administration of a single dose. In the case of oral sustained released dosage form, an effect is for several hours depending upon residence time of formulation in the GIT. The success of a therapy depends on selection of the appropriate delivery system as much as drug itself.1 Sustained release dosage forms are designed to complement pharmaceutical activity of the medication in order to achieve better selectivity and longer duration of action. Captopril belongs to class Angiotensin Converting Enzyme inhibitor (ACE inhibitor). It effects the rennin-Angiotensin system and inhibits the conversion of relatively inactive Angiotensin I to active Angiotensin II. Thus, ACE inhibitors attenuate or abolish responses to Angiotensin I but not to Angiotensin II. Hence the inhibition of ACE therefore may induce the effect unrelated to reducing the level of Angiotensin II. ACE inhibition increase bradykinin synthesis which stimulate prostaglandin biosynthesis. Bradykinin and prostaglandin contribute pharmacological effect of ACE inhibitor. All these effects produce pharmacological actions like vasodilatation etc which ultimately decrease the blood pressure. Captopril is freely water-soluble and has a half-life 1.9 hours. It is usually prescribed to patients who are chronically ill and require long term use for therapeutic benefits. Development of a captopril oral formulation would be a significant advantage for patient compliance accompanied by minimization of the drug side effects as a result of reduction in the drug blood concentration fluctuations, especially in long-term therapy. The aim of this study was to prepare matrix tablets of Captopril using varying proportions of the Xanthan gum and Ethyl cellulose. MATERIALS & METHODS MATERIALS Captopril was purchased from Swapnroop Drugs and Pharmaceuticals (Aurangabad, India)., HPMC K 100,Xanthan gum, PVP K30 purchased from Balaji Drugs, Ethyl cellulose, Lactose are from Modern Industries (Malegaon), and